Adoptive immunotherapy of urologic tumors
- 1 January 1989
- book chapter
- Published by Springer Nature
- Vol. 46, 213-233
- https://doi.org/10.1007/978-1-4613-1595-7_12
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytesCellular Immunology, 1986
- Functional characterization of T lymphocytes propagated from human lung carcinomasClinical Immunology and Immunopathology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancerCancer, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976